Mayzent, Zeposia May Lose Ground in Canada, Report Finds

Mayzent, Zeposia May Lose Ground in Canada, Report Finds

295195

Mayzent, Zeposia May Lose Ground in Canada, Report Finds

Mayzent (siponimod) and Zeposia (ozanimod), the two sphingosine-1-phosphate (S1P) receptor modulators most recently approved in Canada for treating multiple sclerosis (MS), showed strong launches in the country, according to the latest Spherix Global Insights’ report. However, due to several internal and external factors, sustained relevance of these therapies in the MS market “may be harder to achieve,” a Spherix press release summarizing the report noted. The report was part of Spherix’s RealTime Dynamix: Multiple Sclerosis (Canada)…

You must be logged in to read/download the full post.